The insider sales are routine post-vesting diversification by two C-suite executives following a massive earnings beat. The 0.11% of market cap sold is negligible. Focus on the bullish Q2 fundamentals, revenue beat, raised guidance, and narrowing losses, rather than this cluster. Monitor for any unplanned open-market selling by the CEO or CFO, which would be a more material signal.
Drug in focus
INSM drug pipeline →BRINSUPRI
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched in the US (August 2025), EU (November 2025), and Japan (August 2026)
- Next catalyst
- None dated
What to watchBRINSUPRI is already a commercial success with a blockbuster launch trajectory, but the stock has pulled back ~40% from its 52-week high of $212.75. With no imminent binary catalyst (the drug is already approved globally), the investment thesis hinges on continued commercial execution and pipeline progress from Insmed's other assets (TPIP, ARIKAYCE). Watch quarterly prescription trends and any label-expansion updates for brensocatib.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $126.33entry
- T+1 · 3mo ago −2.05%α −1.85% · $123.74
- T+5 · 3mo ago −0.99%α +0.97% · $125.08
- T+20 · 2mo ago +2.44%α +4.19% · $129.41
- T+60 · 11d ago −11.08%α −5.84% · $112.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed's COO and CMO sold a combined $33.1M in stock immediately following a blockbuster Q2 earnings beat (revenue $425.5M vs. $393.4M consensus) and raised guidance. The COO's $32M sale is the dominant event, executed after exercising options at much lower strike prices. While the earnings were strongly bullish, the insider sales are likely liquidity-driven post-vesting and are trivial relative to the $29B market cap (0.11%), making this a neutral cluster signal that does not offset the positive fundamental momentum.
Key Financial Metrics
Key Facts
- COO Roger Adsett sold 239,850 shares for $31.96M on 2026-08-10 after exercising options at $0-$30.46.
- CMO Martina Flammer sold 27,173 shares total for $3.49M on 2026-08-06 after exercising options at $0-$25.83.
- Total insider sales of $33.09M represent just 0.11% of INSM's $29B market cap.
- Sales occurred 4-5 days after Q2 2026 earnings beat: revenue $425.5M vs. $393.4M consensus, raised FY2026 BRINSUPRI guidance to $1.25B-$1.4B.
- All sales were preceded by option exercises at deep in-the-money strike prices, consistent with routine post-vesting diversification.
Financial Impact
Total insider sales of $33.09M, or 0.11% of market cap, immaterial relative to company size.
Risk Factors
- Insider selling could accelerate if the stock continues to rally, creating near-term overhead supply.
- Any future insider sales without corresponding option exercises would be a more bearish signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INSM-1786568700959 |
Track record
24 reports on INSM
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers